Zosano Pharma Corp (OQ:ZSAN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 34790 Ardentech Ct
FREMONT CA 94555-3657
Tel: N/A
Website: www.zosanopharma.com
IR: See website
Key People
John P. Walker
Chairman of the Board
Steven Lo
Chief Executive Officer, Director
Christine E. Matthews
Chief Financial Officer, Principal Financial Officer
Dushyant Pathak
Senior Vice President - Business Development
Eric Scharin
Vice President - Technical Operations
Thorsten von Stein
Chief Medical Officer
Business Overview
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company's Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.
Financial Overview
For the three months ended 31 March 2020, Zosano Pharma Corp revenues was not reported. Net loss decreased 8% to $8.7M. Lower net loss reflects Research and development- bal decrease of 17% to $5.3M (expense), Other income (expense), net increase from $22K to $103K (income), Interest on finance lease obligations decrease of 78% to $2K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.79 to -$0.24.
Employees: 56 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $35.28M as of Mar 31, 2020
Annual revenue (TTM): $0.00M as of Mar 31, 2020
EBITDA (TTM): -$35.53M as of Mar 31, 2020
Net annual income (TTM): -$36.85M as of Mar 31, 2020
Free cash flow (TTM): -$44.92M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 54,361,635 as of May 12, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization